Click on the

 icon above to

 download this

 document in 

 Microsoft 

 Word format.

_____________

 Click on the

 icon above to

 download the

 Budget

 Instructions

 and Forms

 in Microsoft 

 Excel format.

THE DONALD W. REYNOLDS FOUNDATION

CARDIOVASCULAR CLINICAL RESEARCH PROGRAM

Call for Proposals

• Deadline for mandatory letters of intent July 15, 2002

• Deadline for receipt of proposals September 20, 2002

• Meeting for interested prospective applicants June 19, 2002

The Donald W. Reynolds Foundation is an independent philanthropic organization incorporated in Nevada in 1954. It is among the fifty largest foundations in the United States. Its benefactor was widely recognized as an entrepreneur, pioneer and dominant force in the American communications industry.

The Foundation’s Trustees have determined to bring its resources to bear in the fight against heart and vascular diseases. These diseases remain the leading cause of death among Americans. In 1998 the Trustees established the Foundation’s Cardiovascular Clinical Research Program. The first grant under the Program was approved in June 1999 and provided $24 million over four years for the establishment of the Donald W. Reynolds Cardiovascular Clinical Research Center at the University of Texas Southwestern Medical Center at Dallas. A second grant, for the same amount, was made in July 2000 to establish a Reynolds Center at Stanford University.

Program Goals 

The principal goal of the Foundation’s Cardiovascular Clinical Research Program is to accelerate breakthroughs in the treatment and prevention of atherosclerosis and atherosclerotic heart disease through support of path-breaking research in concert with efforts to translate that research into practice in the care of patients and in population-based prevention of these conditions. 

Of particular interest under the Program is the combination of fundamental and discovery research on novel strategies and concepts with potential therapeutic or preventive value and provision for its clinical or preventive application. Clinical trials, health services research, epidemiology and biostatistics are seen as crucial in furthering the Program’s goals. The Foundation is willing to support innovative, high-risk research that could lead to significant paradigm shifts.

A major goal of the Program is to foster collaboration among basic, clinical and health services researchers in a manner that strengthens the fight against atherosclerosis and atherosclerotic heart disease. This includes development of a network of investigators, based within and outside of the Reynolds Centers.

Another important goal of the Program is to strengthen the training of clinical investigators interested in pursuing careers dedicated to fighting atherosclerosis and atherosclerotic heart disease.

Objective of Call for Proposals

The Donald W. Reynolds Foundation solicits interdisciplinary, collaborative proposals from America’s academic health centers for the establishment of additional Donald W. Reynolds Cardiovascular Clinical Research Centers dedicated to fighting atherosclerosis and atherosclerotic heart disease. Specifically, Centers funded under this Program will be expected to:

• Contribute new knowledge that will speed the progress toward a cure for atherosclerotic heart disease.

• Encourage innovative, and possibly high-risk research consistent with the Program’s goals.

• Translate new knowledge into applications that will improve treatment and prevention.

• Demonstrate effective strategies for facilitating translational research and clinical trials. 

• Apply the principles of health services research, epidemiology and biostatistics to the fight against atherosclerotic heart disease.

• Demonstrate effective programs for the education and training of clinical investigators who will become leaders in fighting atherosclerotic heart disease.

• Create innovative and productive approaches for fostering collaboration among scientists across disciplines within and outside of Reynolds Centers.

Substantive Scope

Those considering proposals under this Program are encouraged to design innovative and integrated research and research application strategies targeting one or more topics that offer significant potential for achieving breakthroughs in the pathogenesis, diagnosis, treatment and/or prevention of atherosclerosis and atherosclerotic heart disease. Such strategies typically should entail multiple projects, but those projects should be integrated in a manner that promises greater impact than would be the case were they to be designed and implemented individually. 

A broad range of topics potentially could further the Program’s goals. For that reason, the only restrictions in the choice of topic are that it be focused explicitly on the pathogenesis, diagnosis, treatment and/or prevention of atherosclerosis or atherosclerotic heart disease. The Program is intended to add new dimensions to investigators’ work rather than supporting the simple extension of their current research. Elements of a successful Center proposal may include but need not be limited to: 

• Studying mechanisms involved in the development of vulnerable plaque; identifying vulnerable plaque, retarding its formation, fostering its regression, and minimizing its biological effects, including its rupture.

• Improving the detection of subclinical cardiovascular disease and identifying how such information might be useful in optimizing preventive and therapeutic measures that improve health.

• Stimulating angiogenesis and arteriogenesis; improving coronary blood flow with new drugs and devices; reducing restenosis. 

• Exploring pathogenesis of the dysfunctional heart and ways to improve myocardial function in atherosclerotic heart disease.

• Discovering the molecular and cellular basis and improving management of lethal cardiac arrythmias in atherosclerotic heart disease.

• Identifying pathways and genetic predispositions for development and progression of atherosclerosis.

• Testing the effectiveness of gene therapy through gene transfer in cells, tissues and whole animals.

• Developing and investigating the efficacy of new population-level interventions for treatment and primary and secondary risk factor modification in atherosclerotic heart disease, as well as improving the compliance of individual patients with optimal treatment and prevention measures.

• Interrupting the continuum leading from obesity, hypertension and diabetes to atherosclerosis and atherosclerotic heart disease and the subsequent impact of diabetes upon the clinical course of atherosclerotic heart disease.

• Developing improved methods for translating existing evidence and research into practice in the care of patients and in population-based prevention of atherosclerosis and atherosclerotic heart disease.

• Expanding the methodology for evaluating and improving the quality of cardiovascular care. 
  

Required Center Components  

This initiative seeks to facilitate interaction between investigators with a variety of backgrounds, scientific disciplines, and skills. The common thread drawing them together is an interest in combining fundamental research on novel strategies and concepts with its clinical or preventive application. Some of those supported under a grant may have a strong laboratory focus but they also must be committed to applying the results of their research to improving patient care and prevention. Others would be expected to engage in studying human subjects, with the focus ranging from small groups of patients to populations. 

A proposal for support under this Program must provide for a core group of Donald W. Reynolds Investigators, Associates and Fellows with complementary expertise and interests appropriate for the goals proposed for the institution’s Reynolds Center . While there is some flexibility in the number and configuration of these positions, the Foundation’s preference is the following: 

Reynolds Investigators 

Four established researchers with proven track records who will lead grant-supported research and related activities at the Reynolds Center . Each designated Reynolds Investigator must propose a research project or related activity. 

Two of the Reynolds Investigators will serve as Director and Co-Director of the Center, one directing clinical investigation and the other leading the remaining Center activities. The Center Director and Co-Director should devote at least 25% effort to the funded program and receive at least 25% of their compensation from the grant. The other Reynolds Investigators leading grant-supported research and related activities should devote no less than 20% of their time to that work and receive no less than 20% of their compensation from the grant. The compensation rate for the four Reynolds Investigators should not exceed 150% of the relevant NIH salary cap. 

Reynolds Associates 

Eight investigators who have completed their training and are emerging as independent investigators with great promise in translational research and/or clinical trials, health services research, epidemiology and biostatistics in atherosclerotic heart disease. M.D. investigators will have completed their clinical training. The Foundation expects the Associates to progress toward scientific independence and to obtain independent funding during their training period with the Center. Associates should devote no less than 25% of their time to Reynolds-supported research and related activities; any combination of compensation and research support is permissible and normally should approximate no less than 25% of the individual’s compensation. The compensation rate for Associates should not exceed 150% of the relevant NIH salary cap. Most of the designated Reynolds Associates must be assigned to one or more of the research projects or related activities proposed by the Reynolds Investigators. In some instances, a designated Reynolds Associate may be deemed by the applicant institution to be qualified to lead his or her own research project or related activity. Three of the eight designated Reynolds Associates must propose a separate project or related activity. 

Reynolds Fellows 

At least four physicians who have finished medical school and residency and are pursuing specialization in cardiovascular research and treatment. Fellows should devote no less than 25% of their time to Reynolds -supported research and related activities; any combination of compensation and research support is permissible and normally should approximate no less than 25% of the individual’s compensation. Fellowship compensation should not exceed the institution’s guidelines for fellowship positions. Each designated Reynolds Fellow must be assigned to one or more of the research projects or related activities proposed by the Reynolds Investigators (or in some instances a Reynolds Associate).

Collaboration

The Foundation’s intent is to create a network of institutions and scientists who can interact with one another so as to accelerate developments in improving cardiovascular health.  That network includes the two funded Reynolds Centers at the University of Texas Southwestern Medical Center at Dallas and Stanford University and their associated investigators.  The Foundation’s evaluation of each proposal will consider the extent to which it broadens and/or synergizes with the spectrum of research and training for translation of cardiovascular research and enriches the overall impact of the network of Reynolds Centers and investigators.   

To fulfill the Program’s goal of facilitating network development and collaboration, each proposal must provide explicitly for the active participation in the proposed grantee’s projects of established investigators based in at least three other institutions, either as collaborating investigators or as collaborating consultants.  Often, this collaboration may take the form of independent, but complementary, research projects. The number and mix of such individuals proposed for support under a grant should be appropriate for the projects in which they would participate.  In all cases, they would be expected to play an integral role in the proposed project and to be established investigators.  Those collaborating investigators who intend to pursue independent research must propose separate research projects.  

There are no restrictions as to the time devoted to grant-supported research and related activities by collaborating investigators or consultants from other institutions. The compensation rate for collaborators should not exceed 150% of the relevant NIH salary cap. Adequate documentation must be provided regarding the nature of the time and/or other commitment of the collaborating investigators or consultants.

To assure adequate provision for collaboration, no less than 20% of the total proposed grant must be budgeted for those in other institutions involved in collaborative arrangements. 

Training

Program applicants are encouraged to propose innovative training programs and related arrangements. For example, there might be support for training activities by collaborating investigators in their respective institutions or even multi-institutional training arrangements. Opportunities for exposure to the full breadth of research, from discovery to health services research, should be available. Information should be provided regarding the goals, organization, curriculum, faculty, previous experience, and trainee selection of the training program 

Scale of Program and Individual Grants

The Reynolds Foundation expects to commit up to $48 million under this Call for Proposals. Up to two grants will be awarded, each totaling up to $24 million (including indirect costs; see below) over four years, with a limit of $6 million in each grant year. A favorable review of the Center will result in continued support for a fifth year and an opportunity to renew support for an additional five years. 

Eligibility 

The Foundation will accept proposals from academic health centers in the United States with established cardiovascular disease research activities that provide formal research training opportunities for clinical trainees. The awards are not transferable to other institutions. An institution may submit only one Reynolds Center proposal for the 2002-2003 competition. 

The Center may be composed of more than one institution with individuals and projects at more than one medical school or teaching hospital, provided there is evidence of, and opportunity for a close personal and geographical interaction between Reynolds Investigators, Associates and Fellows. To maintain close inter-project interactions and interdependence, not less than half of the individual projects and half of the shared facilities shall be in the applicant institution. The applicant institution must maintain fiscal responsibility for the Center award. 

The Center Director must be employed by the applicant institution at the time of the application. The Center’s Director, Co-Director and all Reynolds Investigators, Associates, and collaborating investigators and consultants must have an M.D., Ph.D., DO, or equivalent doctoral degree at the time of the application. Fellows must hold an M.D. degree. At the time of application, applicants must be U.S. citizens or foreign nationals holding permanent resident visas. 
Proposals will not be accepted for funding to be administered through any Federal institution or work to be performed by a Federal employee except for employees of the Veterans Administration. 
Proposals must have the institutional approval of the appropriate dean and chief executive officer. 
Institutions receiving grant support under this Program must agree to comply with the Donald W. Reynolds Foundation’s policies governing research program awards. A copy of those policies is included with this Call for Proposals. 

Grant Selection Process

Grants under this initiative will be awarded on a competitive basis by the Foundation’s Trustees, taking into account the recommendations of an expert advisory panel.   

The selection process will be in three steps.  The first step requires the submission of a proposal, as described below.  This will include only relatively brief descriptions of the individual research projects to be undertaken as part of the proposed Reynolds Center activities.   Semi-finalists will be selected based on a review of these proposals by the Foundation’s expert advisory panel.  In the second step, semi-finalists will be invited to submit detailed descriptions of each of the individual research projects described in the proposal.  These will be evaluated in a peer review process managed by the American Heart Association.  In the third step, the Foundation’s expert advisory panel, taking the results of the AHA-managed peer review process into account, will select and invite a small number of finalists to send up to six representatives to Las Vegas to present their proposals to the panel in reverse site visits.  The advisory panel will then make its grant recommendations to the Trustees.

Timetable

A meeting for interested prospective applicants will be held on Wednesday, June 19, 2002 from 10:00 a.m. until noon at the O’Hare Airport Hilton Hotel near Chicago .  Members of the Foundation’s expert advisory panel and staff will be present to discuss the goals of the Cardiovascular Clinical Research Program, this call for proposals and the grant selection process and to answer questions.  Representatives of the University of Texas Southwestern Medical Center at Dallas and Stanford University also will be present to discuss their Reynolds Centers. If you plan to attend, please call the Foundation at (800) 481-8780.  

A letter stating the institution’s intent to submit a proposal must be received by the Foundation by July 15, 2002 . This letter is mandatory. It should tentatively list the names of the senior investigators who are expected to participate in the project, including the names and institutions of collaborating investigators and collaborating consultants. It is understood that some of those named may not be included in the final proposal and that others may be added.  The applicant institution should keep the Foundation informed of any such changes.

Proposals must be received (not postmarked) by the Foundation by 5:00 p.m. Pacific Daylight Time, September 20, 2002 .  A signed original and fourteen copies of the proposal should be submitted.

Semi-finalists will be notified no later than November 8, 2002 .

A signed original and twenty-five copies of the detailed descriptions, utilizing U.S. Public Health Service Form 398, of all individual research projects proposed by semi-finalists must be received (not postmarked) by the American Heart Association by 5:00 p.m. Central Standard Time, January 10, 2003.  An additional ten copies must be received by the Reynolds Foundation no later than January 31, 2003 . (There is a twelve page limit for the Research Plan description – items A-D.)    

Finalists will be notified no later than March 25, 2003 .

Reverse site visits for finalists will be scheduled for April 2003.

Awards will be announced no later than May 1, 2003 .

Normally, grant-supported activities should commence July 1, 2003 .

Letters of intent and proposals should be sent to: 

            The Donald W. Reynolds Foundation

         Cardiovascular Clinical Research Program

         1701 Village Center Circle

         Las Vegas , NV 89134-6303

Twenty-five copies of semi-finalists’ individual research project descriptions should be sent to: 

            The Donald W. Reynolds Foundation

         Cardiovascular Clinical Research Program

         C/O Division of Research Administration

         American Heart Association

         National Center

         7272 Greenville Avenue

         Dallas , TX 75231-4596

(An additional ten copies of semi-finalists’ individual research project  descriptions should be sent to the Reynolds Foundation at the Foundation’s address.)  

Those with questions should contact Richard S. Sharpe, the Reynolds Foundation’s Executive Vice President, at: 

    Telephone:  (800) 481-8780

    Fax:           (702) 804-6035

    E-mail:        richard.sharpe@dwrf.org

Selection Criteria  

The following major factors will be considered in the evaluation of proposals. All of the factors will be entered into the deliberations and the relative weight given each factor may differ from case to case. These factors are not listed in any specific order of priority.

• Strength and nature of the institution’s commitment to the Center.

• Potential impact of the research on the clinical care of patients with atherosclerotic heart disease and/or on prevention of the disease.

• The innovativeness of the research hypotheses that are unique to the Center.

• The innovativeness of the cardiovascular clinical research training program that is proposed for the Center.

• The strength of the multidisciplinary and collaborative approach demonstrated in the proposed faculty, research proposals, and education and training plans, including strategies for linking collaborating investigators and consultants to the Center.

• The qualifications of the proposed Reynolds Investigators, including research accomplishments, experience and productivity, and commitment of time and effort to the proposed Center.

• The qualifications of the proposed Reynolds Associates, including research training, productivity, fellowships and faculty positions.

• The experience of the Director and Co-Director in leadership of interactive and interdisciplinary scientific programs and in management of administrative academic or clinical units with fiscal accountability.

• The quality and productivity of the institution’s current and past cardiovascular research trainees.

• The scientific excellence of the current cardiovascular research program.

• The interest and commitment of the proposers to participate in the network of Reynolds Centers, including collaborations and periodic Reynolds symposia. 

In evaluating the individual research project descriptions submitted by semi-finalists, the American Heart Association’s peer review process will apply the following criteria: 

• Scientific excellence of the research proposal, including originality of ideas, projected scientific impact, soundness of approach, familiarity with pertinent literature and work of other investigators in applicant’s field of interest, and logical organization;

• Qualifications, relevant experience and productivity of the applicant; applicants are expected to be independent as demonstrated by laboratory space assignments, independent publications, and academic title; and

• Adequacy of available facilities, equipment and other resources necessary to the project.

Components of the Proposal  

Proposals should follow the format and page limitations specified below.  

All proposed Reynolds Investigators, Associates, collaborating investigators and consultants, and the appropriate dean and the chief executive officer of the submitting institution should sign the proposal.

Proposals should include the following:

• A cover sheet that includes the name and address of the institution, title of the over-all Center program, amount and term of the requested grant, the proposed date of project initiation, the name and contact information of the individual responsible for the project, and the appropriate signatures, as specified above.

• A summary description, not exceeding one page, of the proposed over-all Center and its program

• A description of the vision for the proposed Center, not exceeding four pages, including:

1. The clear, unifying central theme to which each component project relates and to which each investigator contributes;

2. The rationale for selection of this theme and the component projects;

3. The target goals that are anticipated for the four- year program with special reference to the contributions expected from the investigators.

• A description of the research or related activity proposed by each designated Reynolds Investigator, each of three Reynolds Associates and any collaborating investigator who chooses to propose such a project, including:

1. A one-page summary (similar to that used with PHS 398) of the research or related activity, including activities of any collaborating investigator/consultant;

2. A one-page description of the specific aims of the project; and

3. Up to one page of references.

• A description, not exceeding three pages, of the proposed training program and of relevant current training grants.

• A description, not exceeding four pages, of the existing cardiovascular disease program and history of significant successes in heart research.

• Information (using PHS 398/2590 Biographical Sketch format, not exceeding three pages each) regarding the proposed Director and Co-Director of the Reynolds Research Center , the two other proposed Reynolds Investigators, and the proposed Reynolds Associates.

• Information (using PHS 398/2590 Biographical Sketch format, not exceeding three pages each) regarding proposed collaborating investigators and consultants.

• Information (using PHS 398/2590 Biographical Sketch format, not exceeding three pages each) regarding up to 10 other faculty members at the applicant institution who are significantly associated with research, training or other activities relevant to the proposed Center.

• A list of all physician scientists who have been trained over the past ten years by the applicant institution in cardiovascular disease.

• A list of current residents and fellows who are pursuing specialization in cardiovascular disease and treatment.

• A description, not exceeding one page for each individual, of the research funding available to the proposed Reynolds Investigators and Associates, other relevant faculty and collaborating investigators and consultants and of current and pending applications for funding.

• A description, not exceeding two pages, of relevant collaborative research within the institution and with other institutions.

• A description, not exceeding three pages, of relevant institutional resources, infrastructure, and major research and educational core facilities, including Clinical Research Centers.

• A description, not exceeding one page, of support systems for institutional grants management and the IRB review process for clinical trials and patient-oriented research.

• A detailed budget and budget justification, using the instructions and format attached to this Call for Proposals.

The overall proposal and the individual projects must receive appropriate institutional endorsements in regard to the use of humans, biohazards and animals.

Budget, Indirect Costs and Fringe Benefits

Allowable budget items include investigators’ salaries and fringe benefits, salaries/fringe benefits of the essential technical personnel, supplies, equipment, travel, volunteer subjects cost, publication cost and other project-related expenses, administrative support, including funding for information technology, communications, secretarial services and financial management.  

Additional funds will be provided by the Foundation for travel to Reynolds Foundation cardiovascular symposia, which will be organized occasionally by the Foundation or its grantee(s).

Reynolds Foundation funding may not be used for buildings. Minimal amounts for renovation to install items of equipment may be included, subject to approval by the Foundation. 

Tuition costs or laboratory fees for work leading to an M.D. or Ph.D. are not permitted.  (Special courses or other training are permitted for those holding the M.D. or Ph.D.) 

Items ordinarily considered to be overhead will be allowed only as part of the indirect cost provision. 

The Foundation has established an indirect cost rate of 20% of direct expenditures under the grant, including expenditures under subcontracts and individual projects based in other institutions.  In cases where overhead is paid to subcontractors or other institutions, the combination of such overhead and that paid to the grantee institution may not exceed 20%.   

All fringe benefits are limited to the federally approved rate.

Monitoring and Evaluation  

Grants awarded under this initiative will be subject to monitoring and evaluation by the Reynolds Foundation.  This will entail submission of periodic progress and financial reports and site visits by the Foundation’s expert advisory panel, consultants and/or staff.  

Critical considerations in evaluating a grant include success in securing leverage through additional and continuing funding, accomplishments against plan and productive collaborative activities.  Consideration of a Center’s performance also will include peer-reviewed publications by relevant individuals, participation in symposia sponsored by the Foundation, and new funding obtained by the Reynolds Associates.

Liability

The Donald W. Reynolds Foundation is not responsible for any claim, judgment, award, damages, settlement, negligence or malpractice arising from research, training, or other activities related to an award.  The grantee institution must acknowledge responsibility for activities related to an award, and release the Donald W. Reynolds Foundation from all claims or liability that may arise from the conduct of such activities related to an award resulting from any act or omission on the part of the institution, its employees, agents or representatives. 

May 2002

Attachments:

1. Policies Governing Donald W. Reynolds Foundation Research Program Awards

2. Required Budget Format for Donald W. Reynolds Cardiovascular Clinical Research Center Proposals

____________________________________________________________________________

Policies Governing

Donald W. Reynolds Foundation

Research Program Awards

Policies Of The Donald W. Reynolds Foundation Governing The Use Of Humans And Animals  

With respect to human and animal experimentation, the awardees and department head of the sponsoring institution must affirm:

That the investigations involving human subjects carried out under the grant have been endorsed by the committee on clinical investigation, or other clearly designated appropriate body, of the sponsoring institution; and that any research involving human subjects will conform ethically with the guidelines prescribed by the National Institutes of Health (NIH) including provision of suitable explanation to human subjects or their guardians concerning the experimental design and all significant hazards,  so that they may be in a position to provide appropriate informed consent prior to the investigation; and that research involving animals will conform with the current “Guides for the Care and Use of Laboratory Animals”, National Research Council publication (1996); and with federal laws and regulations; and has been approved by the Institutional Animal Care and Use Committee; and that whenever applicable, the research protocol will be reviewed and approved by the institution’s biohazards committee as well as conforming to NIH guidelines.   

The Donald W. Reynolds Foundation does not fund scientific research that involves the use of human fetal tissue.   

Policies Of The Donald W. Reynolds Foundation Regarding

Investigatory Financial Disclosure/Objectivity In Research

Investigators and institutions are required by the Donald W. Reynolds Foundation to comply with PHS regulations, Final Rule, 42 CFR Part 50, Subpart F, Responsibility of Applicants for Promoting Objectivity in Research.  The intent is to ensure that the design, conduct, or reporting of research funded by the Reynolds Foundation will not be biased by any conflicting financial interest of those investigators responsible for the research.  

In accepting and agreeing to the terms of the grant, the official countersigning the grant letter indicates that an institutional administrative process is in effect to identify and resolve conflicting financial interests of the type described in Subpart 50.605(a) with respect to all research projects for which grant funding is provided by the Reynolds Foundation.   

Patent, Intellectual Property And Technology Transfer Policy 

Of The Donald W. Reynolds Foundation 

Though the primary purpose of the Donald W. Reynolds Foundation (hereinafter designated Reynolds Foundation) in funding scientifically meritorious research is to advance the progress of translational research and clinical trials, health services research, epidemiology and biostatistics in atherosclerotic heart disease by establishing a Reynolds Cardiovascular Clinical Research Center, the Reynolds Foundation recognizes that inventions having public health, scientific_, business or commercial application or value may be made in the course of research supported by the Reynolds Foundation. It is the desire of the Reynolds Foundation that such inventions be administered in such a manner that they are brought into public use at the earliest possible time. The Reynolds Foundation recognizes that this may be best accomplished through patenting, copyrighting, and/or licensing of such inventions.

“lnvention” is any discovery, material, method, process, product, program, software or use, whether or not patented or patentable or copyrighted or copyrightable, that has an application of value such that its use, licensing, lease or sale can generate revenue.

_______________________________________________________

1.    All inventions discovered or arising out of research supported in whole or in part by the Reynolds Foundation which are reduced to practice shall be timely reported to the Reynolds Foundation.

2.   If the institution receiving or disbursing the Reynolds Foundation funds which supported the invention has an acceptable established and applicable patent, intellectual property or technology transfer policy and procedure for administering inventions, the Reynolds Foundation will defer to that policy with the following restrictions:

1. The Reynolds Foundation will be notified of a patent application being made and/or patent being received, of a copyright being asserted, and/or of a license, lease, sale or revenue generating agreement concerning the invention. No patent or patent application, copyright or other intellectual property protection shall be abandoned without prior notification to the Reynolds Foundation and giving the Reynolds Foundation the opportunity to take title to the invention.  

2. Any income derived by the institution from the invention shall be pro-rated to identify that portion of the income that is attributable to the Reynolds Foundation grant’s support for the work or research giving rise to the invention.  The institution must agree that its pro-rated share of such income attributable to the Reynolds Foundation grant shall be used exclusively for support of the institution’s cardiovascular clinical research. 

3.   If the institution does not have an acceptable established and applicable patent, intellectual property or technology transfer policy and procedure for administering inventions, the Reynolds Foundation shall have the right to determine the disposition of the invention rights. In such cases, the Reynolds Foundation may:

a.         Decide that patent or copyright should be or not be filed.

b.         Release the invention to the inventor(s) or inventor's designee.

c.         Submit the invention to a qualified organization for administration

            and licensing, such as Research Corporation Technologies.

d.         Determine by negotiation the fair share of royalty income to be paid

            to the inventor(s).

e.         License or make other arrangements for the application and use of

            the invention on an exclusive or non-exclusive, royalty or royalty-free

            basis as seems reasonable in the circumstances.  

4.    If an invention is made with the joint support of the Reynolds Foundation and an agency or  department of the United States Government, the Reynolds Foundation may defer to the patent, intellectual property or technology transfer policy of that agency or department upon receipt of a written statement by the appropriate agency or department notifying the Reynolds Foundation of its policy and procedure and identifying the rights and interests of the Reynolds Foundation in the invention in question.  

5.   If any invention is made with the joint support of the Reynolds Foundation and some other health agency or funding organization, not an agency or department of the United States Government, that other organization, the inventor(s), the inventor's institution, and the Reynolds Foundation shall negotiate a mutually satisfactory disposition of the invention rights.

Standards On Falsification Of Scientific Data,

Plagiarism, And Scientific Misconduct

STATEMENT OF PRINCIPLE AND PURPOSE  

The Donald W. Reynolds Foundation requires highly ethical scientific behavior in all of its programs and activities. The Donald W. Reynolds Foundation endorses the principles of the Association of American Medical Colleges (AAMC) report "The Maintenance of High Ethical Standards in the Conduct of Research". This statement serves as a guideline when allegations are made or indications arise of falsification of scientific data_, plagiarism, or other scientific misconduct in research funded by the Reynolds Foundation.

REYNOLDS FOUNDATION FUNDED SCIENTIST SUSPECTED OF VIOLATION

1. When a credible allegation or reasonable indication of scientific misconduct by a Reynolds Foundation funded scientist, or applicant for Reynolds Foundation funding, arises and when a determination is made by the Reynolds Foundation that the institution has an acceptable procedure to investigate and resolve the allegation, the Reynolds Foundation ordinarily will allow the institution to investigate and resolve the allegation.  However, the Reynolds Foundation reserves the right to itself conduct or call for an independent investigation resulting in findings or suggestions.

2. When the institutional procedure is found not to be acceptable or there is no institutional procedure, the Reynolds Foundation shall determine an appropriate course of action including, but not limited to, conducting an independent investigation, or requesting an independent investigation by a third party, making findings or recommendations, seeking restitution from the scientist or institution, notifying other funding or appropriate agencies, or requesting retractions of published articles or studies.

The officers of the Board of Trustees of the Reynolds Foundation are the responsible party in consultation with the chairperson of the Scientific Advisory Panel.  

PROCEDURE

In each of the above situations the responsible parties, in consultation with the Reynolds Foundation's President, shall determine a specific course of action based upon the particular facts and circumstances of the matter. The scientist(s) against whom an allegation or indication of scientific misconduct arises shall be permitted a reasonable opportunity to respond or explain before the Reynolds Foundation takes final action in the matter. Though the intent of this Standard is to protect the reputation of the Reynolds Foundation and the integrity of its funded research programs and activities, due regard also will be given to the protection of the reputation of the involved scientist(s).

Required Budget Format for Donald W. Reynolds Cardiovascular Clinical Research Center Proposals

An electronic version of these instructions and the required budget format can be downloaded from this web site via the link at the top of this page.  A diskette is available by calling (800) 481-8780.

Proposed Budget for Donald W. Reynolds Cardiovascular Clinical Research Center

Applicant Institution:                                                                                                            

I. Center Budget

 

A. Salary and Fringe Benefits of Reynolds Members
Name, Degree	Title/Role	% Effort	1	Year One	Year Two	Year Three	Year Four	Total
1.	Investigator/	1	Salary Fringe	1	1	1	1	1
				1	1	1	1	1
2.	Investigator/	1	Salary Fringe	1	1	1	1	1
				1	1	1	1	1
3.	Investigator/	1	Salary Fringe	1	1	1	1	1
				1	1	1	1	1
4.	Investigator/	1	Salary Fringe	1	1	1